August 11, 2020 -- AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate from its Seattle facility.
NVX-CoV2373 is Novavax's stable prefusion protein vaccine made using nanoparticle technology. AGC will optimize process development for scaled-up production of Matrix-M to enable Novavax to deliver a worldwide supply of the vaccine in 2020 and 2021.
AGC is already providing contract development and manufacturing organization services to Novavax for MatrixM from its facility in Copenhagen.